2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155944
    Isbufylline 90162-60-0 98%
    Isbufylline is a Phosphodiesterase inhibitor. Isbufylline is orally available. Isbufylline can be used in the research of respiratory diseases and inflammation such as asthma and pneumonia.
    Isbufylline
  • HY-155960
    SH491 2975285-28-8 98%
    SH491 (Compound 33) is an antiosteoporosis agent. SH491 inhibits RANKL-induced osteoclast differentiation on bone-marrow-derived monocytes (BMMs) (IC50: 11.8 nM). SH491 inhibits the expression of osteoclastogenesis-related marker genes (TRAP, CTSK, MMP-9, and ATPase v0d2) and proteins (TRAP, CTSK, MMP-9).
    SH491
  • HY-155970
    Urease-IN-7 1129406-54-7 98%
    Urease-IN-7 (Compound 5k) is a competitive Urease inhibitor (IC50: 3.33 μM, Ki: 3.62 μM). Urease-IN-7 can be used for research of peptic and gastric ulcers.
    Urease-IN-7
  • HY-155973
    Urease-IN-8 517906-16-0 98%
    Urease-IN-8 (Compound 5e) is a competitive Urease inhibitor (IC50: 3.51 μM, Ki: 3.11 μM). Urease-IN-8 can be used for research of peptic and gastric ulcers.
    Urease-IN-8
  • HY-155975
    PI3Kδ-IN-14 3038119-14-8 98%
    PI3Kδ-IN-14 (Compound (S)-29) is a selective PI3Kδ inhibitor (IC50: 0.8 nM, Kd: 84.8 nM). PI3Kδ-IN-14 binds to the ATP-binding site of the kinase domain of PI3Kδ. PI3Kδ-IN-14 has anti-inflammatory activity by inhibiting the PI3K/AKT pathway. PI3Kδ-IN-14 ameliorates acute lung injury (ALI).
    PI3Kδ-IN-14
  • HY-155997
    Anti-inflammatory agent 56 2413127-32-7 98%
    Anti-inflammatory agent 56 (Compound 9) is a selective COX-2 inhibitor (IC50: 0.54 μM). Anti-inflammatory agent 56 has anti-oxidant and anti-inflammatory effects. Anti-inflammatory agent 56 inhibits oxidative stress induced cell death. Anti-inflammatory agent 56 inhibits oxidative stress and neuroinflammation by inhibiting Keap1, COX-2 and iNOS. Anti-inflammatory agent 56 has low acute toxicity in mice (LD50: 1000 mg/kg).
    Anti-inflammatory agent 56
  • HY-156061
    NAP-1 131721-28-3 98%
    NAP-1 is a compound with agent that can suppress or relieve pain. effects. NAP-1 enhances the inhibitory current by binding to a specific site of GABAaR, resulting in a narcotic effect. NAP-1 can be used in research to develop clinical agent that can suppress or relieve pain.
    NAP-1
  • HY-156089
    Triptoquinone H 268541-23-7 98%
    Triptoquinone H is a class of natural product isolated from traditional Chinese medicine Tripterygium hypoglaucu. Triptoquinone H has strong cytotoxic, immunomodulatory and anti-inflammatory activities. Triptoquinone H can be used for cancer or inflammatory diseases research.
    Triptoquinone H
  • HY-156121
    NLRP3-IN-20 2428478-22-0 98%
    NLRP3-IN-20 (compound 11) is an orally available inhibitor of the NLRP3 inflammasome with an IC50 of 25 nM for IL-1β secretion. NLRP3-IN-20 has excellent pharmacokinetic properties and demonstrated significant efficacy in models of non-alcoholic steatohepatitis, fatal septic shock, and colitis.
    NLRP3-IN-20
  • HY-156175
    TLR7 agonist 14 2832199-45-6 98%
    TLR7 agonist 14 (compound 17b) is a highly potent TLR7 agonist with an EC50 of 18 nM. TLR7 agonist 14 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.
    TLR7 agonist 14
  • HY-156176
    TLR7 agonist 15 2832199-53-6 98%
    TLR7 agonist 15 (compound 16b) is a highly potent TLR7 agonist with an EC50 of 18 nM. TLR7 agonist 15 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.
    TLR7 agonist 15
  • HY-156177
    TLR7 agonist 16 2832199-56-9 98%
    TLR7 agonist 16 (compound 16d) is a highly potent TLR7 agonist with an EC50 of 18 nM. TLR7 agonist 16 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations.
    TLR7 agonist 16
  • HY-156196
    BI 894416 1810059-82-5
    BI 894416 is a spleen tyrosine kinase (SYK) inhibitor. BI 894416 has a deuterium-labeled derivative that can be used as an internal standard for bioanalytical studies. BI 894416 is applicable to the research of severe asthma.
    BI 894416
  • HY-156203
    MRS4608 2370976-04-6
    MRS4608 (Compound 17) is a selective P2Y14 receptor antagonist with IC50 values of 20 (hP2Y14R) and 21.4 nM (mP2Y14R). MRS4608 has anti-inflammatory activity and can reduce the infiltration of eosinophils. MRS4608 can be used for the researches of inflammation and immunology, such as asthma.
    MRS4608
  • HY-156216
    FPL 52757 37467-41-7 98%
    FPL 52757 is an orally active antiallergic agent. FPL 52757 can be used in the research of asthma.
    FPL 52757
  • HY-156220
    MRS4654 2765570-58-7
    MRS4654 is an efficient and neutral P2Y14R (hP2Y14R IC50 = 15.0 nM, mP2Y14R IC50 = 18.6 nM) antagonist. MRS4654 has analgesic and anti-inflammatory effects. MRS4654 can be used for research on asthma and neuropathic pain.
    MRS4654
  • HY-156241
    Meliadubin B 98%
    Meliadubin B is a natural triterpenoid with significant inflammatory inhibition effect toward superoxide anion generation in human neutrophils (EC50 of 5.54 μM). Meliadubin B inhibits inducible nitric oxide synthase. Meliadubin B shows remarkable inhibition against the rice pathogenic fungus Magnaporthe oryzae with IC50 of 182.50 μM.
    Meliadubin B
  • HY-156254
    COX-2-IN-35 236107-61-2 98%
    COX-2-IN-35 (compound 7) is a selective COX-2 inhibitor with an IC50 of 4.37 nM. COX-2-IN-35 has anti-inflammatory activity.
    COX-2-IN-35
  • HY-156290
    SAP-04 3053678-30-8 98%
    SAP-04 is a potent and orally active STING agonist. SAP-04 exhibits potent immunomodulatory effects for cancer therapy.
    SAP-04
  • HY-156329
    sEH/FLAP-IN-1 98%
    sEH/FLAP-IN-1 (Compound 46A) is a sEH/FLAP inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC50: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC50: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases.
    sEH/FLAP-IN-1
Cat. No. Product Name / Synonyms Application Reactivity